



International benchmarking - life science

In December 2006, VINNOVA was commissioned by the Swedish Government to perform an international study to shed light on the competitiveness of the Swedish sectorial innovation systems of pharmaceuticals, biotechnology and medical technology in international comparison.

The study will include analyses in three main focus areas in an innovation system perspective:

- Key players in the Swedish innovation system, who they are and their position in an international comparison
- Trends, initiatives and commitments in other countries/regions
- Comparative case studies to investigate the competitiveness of the Swedish innovation system

The main question being “What structure, growth and development capacity does the Swedish pharmaceuticals, biotechnology and medical technology industry have compared to other countries/regions excelling in this field?”

VINNOVA is obligated to present the final report of this project June 30, 2009 but the results have also been reported November 30, 2007, May 31, 2008 and November 30, 2008. The latest synthesis report was published 080531.

Underpinning studies and reports

Below a number of studies which are underpinning the future final report are listed. These studies have been performed within the project or are financed/co-financed and/or commissioned by the project. Some of the studies listed are still on-going and therefore a written report is not yet available (labeled: forthcoming) and other reports are available but not in their final version (labeled: preliminary version). Also, some studies will not be made public (labeled: working material) but the results will be used for the final report.

**For more information and access to published studies:
www.vinnova.se/life_science_benchmarking**

Industry focus

- **Why is Danish life science thriving? A case study of the life science industry in Denmark**, S. Gestrelus, MVA [VINNOVA VA 2008:9]
- **National and regional cluster profiles – Companies in biotechnology, pharmaceuticals and medical technology in Denmark in comparison with Sweden**, S. Gestrelus, Medicon Valley Alliance, A. Sandström, VINNOVA and T. Dolk, Addendi AB [VINNOVA VA 2008:10]
- **Biotechnology, pharmaceuticals and medical technology in Sweden 2007 - National and regional cluster profiles**, H. Bergqvist and A. Sandström, VINNOVA and T. Dolk, Addendi AB [VINNOVA VA 2007:16]
- **Regional cluster profile – Companies in biotechnology and pharmaceuticals in Cambridge, UK**, H. Bergqvist and A. Sandström, VINNOVA and T. Dolk, Addendi AB [working material]
- **Investment climate – Utländska investeringar i den svenska life science-industrin, framgångar på ett sluttande plan**, B. Bergstrand, BBD Corporate Communications (ISA, LIF and VINNOVA)
- **Looking over the shoulders of giants – A study of the geography of big pharma R&D and manufacturing operations**, J. Lindman, J. Timsjö and N. Özbek [VINNOVA VA 2008:13]
- **Pipeline analysis – An analysis of the clinical development pipeline in the Swedish biotech industry 2007**, SwedenBIO, ISA and VINNOVA
- **Pipeline analysis – An analysis of the clinical development pipeline in the Swedish biotech industry 2008**, SwedenBIO, ISA and VINNOVA

Research and innovation environments

- **Genomics and Proteomics** Stanford – KTH, A. Branting and A. Sandström, VINNOVA [working material]
- **Forest Biotechnology** Umeå Plant Science Centre (UPSC), J. Brändström, P. Sandgren and A. Sandström, VINNOVA
- **Neuroscience** Columbia University – Karolinska Institutet, M. Wikström ITPS Washington



- **Medical Devices** Stanford, E. Pineiro and B. Guve, CTMH KTH

Key technology areas

- **Action MedTech - Key Measures for Growing the Medical Device Industry in Sweden**, McKinsey
- **Tissue engineering and regenerative medicine: Swedish possibilities within Tissue Engineering and Regenerative Medicine**, A. Rickne, Lund University and The Dahmén Institute and A. Sandström VINNOVA [VINNOVA VA 2009:04]
- **Chemical Biology - Initiatives in USA**, M. Wikström, ITPS Washington
- **Systems Biology and Nanomedicine - Initiatives in USA**, M. Wikström, ITPS Washington [forthcoming]
- **Industrial biotechnology**, M. Jarekrans, VINNOVA

Country studies

- **Canada:** [forthcoming]
- **China:** B. Hammarberg, ABD Life Sciences Ltd.[working material]
- **Denmark:**
 - Why is Danish life science thriving? A case study of the life science industry in Denmark, S. Gestrelus, MVA [VINNOVA VA 2008:9]
 - National and regional cluster profiles – Companies in biotechnology, pharmaceuticals and medical technology in Denmark in comparison with Sweden, S. Gestrelus, MVA, A. Sandström, VINNOVA and T. Dolk, Addendi AB [VINNOVA VA 2008:10]
- **Japan:** L. Stenberg, VINNOVA [preliminary version]
- **Singapore:** Singapore – Aiming to create the Biopolis of Asia, A. Sandström [VINNOVA VA 2009:13]
- **South Korea:** B. Hammarberg, ABD Life Sciences Ltd. [working material]
- **United Kingdom:**
 - A benchmarking study of the Swedish and British life science innovation systems – Comparison of policies and funding, H. Bergqvist [VINNOVA VA 2008:12]
- **USA:** [forthcoming]

Contact

Anna Sandström, VINNOVA, phone +46 8 473 30 57,
e-mail Anna.Sandstrom@VINNOVA.se